Agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
==== Case study ==== The Kennewick Man is a notable example of human remains caught in a struggle between scientific merit and cultural traditions. Since his discovery in 1996, his fate has been the topic of great controversy. As one of the oldest well-preserved ancient skeletons found in America, scientists are eager to conduct various testing on the remains. Native American groups, however, have been adamantly calling for his repatriation and reburial, as per their traditions.
{\displaystyle \mathrm {|p_{\uparrow }\rangle ={\tfrac {1}{\sqrt {18}}}\left(2|u_{\uparrow }d_{\downarrow }u_{\uparrow }\rangle +2|u_{\uparrow }u_{\uparrow }d_{\downarrow }\rangle +2|d_{\downarrow }u_{\uparrow }u_{\uparrow }\rangle -|u_{\uparrow }u_{\downarrow }d_{\uparrow }\rangle -|u_{\uparrow }d_{\uparrow }u_{\downarrow }\rangle -|u_{\downarrow }d_{\uparrow }u_{\uparrow }\rangle -|d_{\uparrow }u_{\downarrow }u_{\uparrow }\rangle -|d_{\uparrow }u_{\uparrow }u_{\downarrow }\rangle -|u_{\downarrow }u_{\uparrow }d_{\uparrow }\rangle \right)} .}
=== Lisa Dearn === Lisa Dearn (Chloe Pirrie) is the deputy energy secretary leading the government inquest against Lumi following its collapse. She presses Robert and Henry with pointed questions about Pierpoint's overvaluation of Lumi, as well as Henry's sexual harassment of his employees. In series 4, Lisa is now Secretary of State for Business and Trade. Her far-left views trouble Lord Norton, who is concerned about the waning influence of legacy media under the new Labour government, and perceives her stance as anti-business. She and Minister for Industry Jennifer Bevan meet with Henry, now CEO of payment processing startup Tender, and CFO Whitney Halberstram, when the two seek regulatory approval for a merger with IBN Bauer Bank. Lisa is skeptical of the merger, deeming it monopolistic and self-serving on Henry's part, but the Prime Minister's chief of staff Ricky Martyn arrives to pressure the regulator into approving the merger lest Labour appear anti-business, with Bevan implied to have engineered the intervention. Government support for Tender forces Lisa to publicly back the company as beneficial to the UK consumer during the launch of its banking app, despite her personal skepticism and disgust for Henry. After news breaks of Tender's fraud, Yasmin plots to pin the company's failure on the Labour government, and circulates a lie in the press that Dearn suppressed an internal memo voicing concerns about Tender while expediting Tender's banking license and regulatory approvals.
Stachys affinis, commonly called crosne, Chinese artichoke, Japanese artichoke, knotroot, or artichoke betony, is a perennial herbaceous plant of the family Lamiaceae, originating from China. Its rhizome is a root vegetable that can be eaten raw, pickled, dried or cooked.
Sources: en.wikipedia.org
A position frequency matrix (PFM) records the position-dependent frequency of each residue or nucleotide. PFMs can be experimentally determined from SELEX experiments or computationally discovered by tools such as MEME using hidden Markov models. A position weight matrix (PWM) contains log odds weights for computing a match score. A cutoff is needed to specify whether an input sequence matches the motif or not. PWMs are calculated from PFMs. PWMs are also known as PSSMs. An example of a PFM from the TRANSFAC database for the transcription factor AP-1:
== Overdose == There have been a handful of cases of fatal overdose with LSD, psilocybin, and mescaline. There have also been cases of death with dimethyltryptamine (DMT), 5-MeO-DMT, 2C-B, Bromo-DragonFLY, NBOMes like 25I-NBOMe, and other psychedelics. LSD and psilocybin appear to have very wide margins of safety with overdose, whereas mescaline and 2C-B have much narrower margins, and NBOMes appear to be especially toxic and uniquely linked to serotonin syndrome-type symptoms. Major psychedelics like LSD and psilocybin do not cause serotonin syndrome, which is thought to be due to the fact that they act as partial agonists of the serotonin 5-HT2A receptor. Conversely, psychedelics like NBOMes have higher activational efficacy at this receptor. In terms of extrapolated human lethal doses based on animal studies and human case reports, lethal doses of psychedelics relative to typical recreational doses are estimated to be 1,000-fold for LSD, 200-fold for psilocybin, 50-fold for oral DMT (as ayahuasca), and 24-fold for mescaline. Estimates for other psychedelics, like 5-MeO-DMT and 2C-B, could not be made. LSD has been assessed in clinical studies at doses of up to 800 μg, or 8-fold the typical dose. However, other studies reported use of LSD at doses of up to 2,000 μg intramuscularly in some individuals, or more than 20 times the typical dose.
=== Pancreas === The human fetal pancreas begins to develop by the fourth week of gestation. Five weeks later, the pancreatic alpha and beta cells have begun to emerge. Reaching eight to ten weeks into development, the pancreas starts producing insulin, glucagon, somatostatin, and pancreatic polypeptide. During the early stages of fetal development, the number of pancreatic alpha cells outnumbers the number of pancreatic beta cells. The alpha cells reach their peak in the middle stage of gestation. From the middle stage until term, the beta cells continue to increase in number until they reach an approximate 1:1 ratio with the alpha cells. The insulin concentration within the fetal pancreas is 3.6 pmol/g at seven to ten weeks, which rises to 30 pmol/g at 16–25 weeks of gestation. Near term, the insulin concentration increases to 93 pmol/g. The endocrine cells have dispersed throughout the body within 10 weeks. At 31 weeks of development, the islets of Langerhans have differentiated. While the fetal pancreas has functional beta cells by 14 to 24 weeks of gestation, the amount of insulin that is released into the bloodstream is relatively low. In a study of pregnant women carrying fetuses in the mid-gestation and near term stages of development, the fetuses did not have an increase in plasma insulin levels in response to injections of high levels of glucose. In contrast to insulin, the fetal plasma glucagon levels are relatively high and continue to increase during development.
=== Drug delivery technologies for outer space === The need for developing drug delivery mechanisms that can accurately control dose frequency, concentration, and amount, for extreme conditions has grown as astronauts take on more extreme space exploration missions. Regenerative therapies have also gained prominence in space medicine. Microgravity conditions lead to bone loss due to repressing osteoblast growth, contributing to traumatic fractures, injuries, and extensive wound generation, requiring surgical intervention. Using a concept called facilitated endogenous repair, scientists are developing scaffolds to deliver drugs or other agents to promote normal physiology at an injury site. In addition, tunable nanoparticles are also being investigated to maintain mechanical integrity when distributed to bone injuries for repair.
Moroidin and its analogous celogentins all have activity comparable to that of vinblastine, and a third group of celogentins all have reduced activity. In contrast, stephanotic acid, a cyclic compound analogous only to the left-hand ring and containing the same Leu-His linkage, has no anti-mitotic activity. Other anti-tubulin agents used as chemotherapy agents have painful side effects known as neuropathy when the drugs are exposed to tissue. Although the exact mechanism for the cause of neuropathy is unknown, it is thought to be related to the degradation of microtubules, which are essential components of neurons.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.